⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449844 | 1.00 | — | — | |
| SCHEMBL24135671 | 0.87 | SIGMAR1 (0.64) | — | |
| SCHEMBL19861948 | 0.78 | — | — | |
| SCHEMBL16684332 | 0.70 | EPHX1 (0.33) | — | |
| SCHEMBL13271754 | 0.68 | MEN1 (0.30) | — | |
| SCHEMBL8272407 | 0.67 | — | — | |
| SCHEMBL10395392 | 0.67 | SIGMAR1 (0.52) | — | |
| SCHEMBL21017344 | 0.67 | PKM (0.31) | — | |
| SCHEMBL23902536 | 0.66 | CHRNB2 (0.31) | — | |
| Iodide SCHEMBL1544786 | 0.65 | SIGMAR1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-2258365-B1 | USE OF ORGANIC COMPOUNDS FOR IMMUNOPOTENTIATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2013-05-29 | — | — | EP | disclosed |
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7384942-B2 | 3-(2,4-dichlorophenyl)-5-bromoyrazine-2-ylamine; inhibiting the formation of neurofibrillary tangles; neurodegenerative, brain disorders; treatment of Alzheimer's disease with one or more additional agents donepezil or tacrine; anticarcinogenic, antiischemic, antidiabetic; insulin resistance | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| EP-1237880-B1 | PYRAZINE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244109-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |
| US-7250443-B2 | Pyrrole based inhibitors of glycogen synthase kinase 3 | CHIRON CORPORATION (US) | 2007-07-31 | — | — | US | disclosed |